Holen Sie sich die Stockscreener-App
12.39
10.54%
-1.46
Handel nachbörslich:
14.00
1.61
+12.99%
Schlusskurs vom Vortag:
$13.85
Offen:
$13.64
24-Stunden-Volumen:
268.78K
Relative Volume:
2.13
Marktkapitalisierung:
$108.19M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-619.50
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
-15.54%
1M Leistung:
+67.43%
6M Leistung:
-32.04%
1J Leistung:
-49.63%
1-Tages-Spanne:
$11.15
$13.70
1-Wochen-Bereich:
$11.15
$14.78
52-Wochen-Spanne:
$6.53
$29.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
12.39 | 128.10M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Seres Therapeutics Inc. Stock Analysis and ForecastConsistently exceptional gains - jammulinksnews.com
Is Seres Therapeutics Inc. a good long term investmentMarket-leading capital gains - jammulinksnews.com
Seres Therapeutics stock jumps after naming co-CEOs By Investing.com - Investing.com Canada
Seres Therapeutics (MCRB) Announces Transition in Executive Lead - GuruFocus
Seres Therapeutics Announces Leadership Transition - The Manila Times
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - The Manila Times
What drives Seres Therapeutics Inc. stock priceExplosive market performance - jammulinksnews.com
Seres Therapeutics to Host Conference Call on August 6, 2025, to Discuss Q2 Financial Results and Business Updates - Quiver Quantitative
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions - Yahoo Finance
individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st
What analysts say about Seres Therapeutics Inc. stockDynamic investment opportunities - jammulinksnews.com
what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser
How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser
What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser
How Seres Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
Why Seres Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser
Seres Therapeutics Soars 21%—What’s Fueling the Biotech Breakout? - AInvest
5 Best Microbiome Companies (July 2025) - Securities.io
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell 3000E Index - MarketScreener
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell Microcap Growth Index - MarketScreener
Seres Therapeutics May 2025 slides: SER-155 shows 77% infection reduction in transplant patients - Investing.com
FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus
Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.
Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World
Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus
Seres Therapeutics reports promising biomarker data - Investing.com
Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times
Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts
Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com
Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):